Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007146086 - CREATINE PRODRUGS, COMPOSITIONS AND USES THEREOF

Publication Number WO/2007/146086
Publication Date 21.12.2007
International Application No. PCT/US2007/013455
International Filing Date 06.06.2007
IPC
C07C 279/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
279Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups
20containing any of the groups X being a hetero atom, Y being any atom, e.g. acylguanidines
24Y being a hetero atom
A61K 31/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
CPC
A61K 47/542
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
542Carboxylic acids, e.g. a fatty acid or an amino acid
A61K 49/0008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
C07C 279/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
279Derivatives of guanidine, i.e. compounds containing the group , the singly-bound nitrogen atoms not being part of nitro or nitroso groups
20containing any of the groups , X being a hetero atom, Y being any atom, e.g. acylguanidines
22Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
C07C 279/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
279Derivatives of guanidine, i.e. compounds containing the group , the singly-bound nitrogen atoms not being part of nitro or nitroso groups
20containing any of the groups , X being a hetero atom, Y being any atom, e.g. acylguanidines
24Y being a hetero atom
C07D 317/36
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
317Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
08having the hetero atoms in positions 1 and 3
10not condensed with other rings
32with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
34Oxygen atoms
36Alkylene carbonates; Substituted alkylene carbonates
Applicants
  • XENOPORT, INC. [US]/[US] (AllExceptUS)
  • GAO, Qingzhi [CN]/[US] (UsOnly)
  • ZERANGUE, Noa [US]/[US] (UsOnly)
  • DOWER, William J. [US]/[US] (UsOnly)
Inventors
  • GAO, Qingzhi
  • ZERANGUE, Noa
  • DOWER, William J.
Agents
  • FORDIS, Jean B.
Priority Data
60/811,08806.06.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CREATINE PRODRUGS, COMPOSITIONS AND USES THEREOF
(FR) PROMÉDICAMENTS À BASE DE CRÉATINE, COMPOSITIONS ET LEURS UTILISATIONS
Abstract
(EN)
Membrane permeable prodrugs of creatine, pharmaceutical compositions comprising membrane permeable prodrugs of creatine, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine or pharmaceutical compositions thereof are disclosed.
(FR)
La présente invention concerne des promédicaments à base de créatine perméables aux membranes, des compositions pharmaceutiques contenant lesdits promédicaments à base de créatine perméables aux membranes, et des procédés destinés au traitement de maladies telles qu'une ischémie, une défaillance cardiaque, et des troubles neurodégénératifs, les procédés consistant à administrer les promédicaments à base de créatine ou des compositions pharmaceutiques les contenant.
Latest bibliographic data on file with the International Bureau